Gavin Corcoran - 31 Mar 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Director
Signature
/s/ Christopher Hayes, Attormey-in-Fact
Issuer symbol
VRCA
Transactions as of
31 Mar 2025
Net transactions value
$0
Form type
4
Filing time
02 Apr 2025, 16:32:51 UTC
Next filing
09 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Stock Option (right to buy) Award $0 +17,502 $0.000000 17,502 31 Mar 2025 Common Stock 17,502 $0.4400 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3rd of the total shares subject to the option shall vest on March 31, 2026, and 1/36th of the total shares subject to the option shall vest in 24 monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.